Jim Simons
SGTX

Jim Simons’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Jim Simons’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,441
Closed -$90K – 4422
2023
Q1 		$90K Sell
7,441
-6,798
-48% -$70.6K ﹤0.01% 3521
2022
Q4 		$65K Buy
14,239
+2,215
+18% +$12.6K ﹤0.01% 3742
2022
Q3 		$79K Sell
12,024
-5,535
-32% -$50.5K ﹤0.01% 3659
2022
Q2 		$189K Sell
17,559
-3,641
-17% -$49K ﹤0.01% 3672
2022
Q1 		$405K Buy
21,200
+12,053
+132% +$269K ﹤0.01% 3317
2021
Q4 		$328K Buy
9,147
+6,893
+306% +$392K ﹤0.01% 3300
2021
Q3 		$166K Buy
+2,254
New +$173K ﹤0.01% 3244

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jim Simons's SGTX Position: Q2 2023 in Review

Jim Simons sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2023, closing a stake of 7,441 shares — an estimated $90K sold.

Jim Simons first reported a position in SGTX in Q3 2021 and held it in 7 quarters. The position peaked at $405K in Q1 2022. 16 funds tracked by Wall St. Rank hold SGTX as of Q2 2023.

  • Jim Simons reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Jim Simons sold 7,441 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $90K.
  • Jim Simons first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
  • Jim Simons's Sigilon Therapeutics, Inc. Common Stock position peaked at $405K in Q1 2022.
  • 16 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.